JP2008545653A - 抗腫瘍組成物及び方法 - Google Patents

抗腫瘍組成物及び方法 Download PDF

Info

Publication number
JP2008545653A
JP2008545653A JP2008512428A JP2008512428A JP2008545653A JP 2008545653 A JP2008545653 A JP 2008545653A JP 2008512428 A JP2008512428 A JP 2008512428A JP 2008512428 A JP2008512428 A JP 2008512428A JP 2008545653 A JP2008545653 A JP 2008545653A
Authority
JP
Japan
Prior art keywords
adenine phosphoribosyltransferase
pnp
nucleic acid
purine nucleoside
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2008512428A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008545653A5 (enExample
Inventor
エリック ソーシャー
ウィリアム パーカー
ジョン エス ホン
Original Assignee
ユーエイビー リサーチ ファンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーエイビー リサーチ ファンデーション filed Critical ユーエイビー リサーチ ファンデーション
Publication of JP2008545653A publication Critical patent/JP2008545653A/ja
Publication of JP2008545653A5 publication Critical patent/JP2008545653A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1077Pentosyltransferases (2.4.2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241Nucleotidyltransferases (2.7.7)
    • C12N9/1258Polyribonucleotide nucleotidyltransferase (2.7.7.8), i.e. polynucleotide phosphorylase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/02Pentosyltransferases (2.4.2)
    • C12Y204/02007Adenine phosphoribosyltransferase (2.4.2.7)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2008512428A 2005-05-16 2006-05-16 抗腫瘍組成物及び方法 Abandoned JP2008545653A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68130505P 2005-05-16 2005-05-16
PCT/US2006/018844 WO2006124847A2 (en) 2005-05-16 2006-05-16 Anti-tumoral compositions and methods

Publications (2)

Publication Number Publication Date
JP2008545653A true JP2008545653A (ja) 2008-12-18
JP2008545653A5 JP2008545653A5 (enExample) 2009-07-02

Family

ID=37432012

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008512428A Abandoned JP2008545653A (ja) 2005-05-16 2006-05-16 抗腫瘍組成物及び方法

Country Status (5)

Country Link
US (1) US20100151572A1 (enExample)
EP (1) EP1898956A4 (enExample)
JP (1) JP2008545653A (enExample)
CA (1) CA2614608A1 (enExample)
WO (1) WO2006124847A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
WO2012112984A2 (en) 2011-02-18 2012-08-23 The Uab Research Foundation Enhanced therapeutic usage of a purine nucleoside phosphorylase or nucleoside hydrolase prodrug related applications
CN111925997B (zh) * 2020-06-05 2023-04-14 浙江理工大学绍兴生物医药研究院有限公司 表达白介素33的重组溶瘤腺病毒的构建及其应用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6491905B1 (en) * 1993-09-14 2002-12-10 The Uab Research Foundation Recombinant bacterial cells for delivery of PNP to tumor cells
AU2003297318A1 (en) * 2002-12-20 2004-07-22 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.

Also Published As

Publication number Publication date
EP1898956A2 (en) 2008-03-19
WO2006124847A3 (en) 2007-10-04
US20100151572A1 (en) 2010-06-17
WO2006124847A2 (en) 2006-11-23
CA2614608A1 (en) 2006-11-23
EP1898956A4 (en) 2008-07-23

Similar Documents

Publication Publication Date Title
van Dillen et al. Influence of the bystander effect on HSV-tk/GCV gene therapy. A review.
RU2557312C2 (ru) Поксвирусные онколитические векторы
EP2212345B1 (en) Poxviral oncolytic vectors
US7037718B2 (en) Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
KR101726390B1 (ko) 뉴클레오시드 프로드럭의 효소 활성자로서의 퓨린 뉴클레오시드 인산화효소
EP1135513B2 (en) Adenovirus-mediated gene therapy
US6423692B2 (en) Method of enhancing the effectiveness of DCK phosphorylated molecules
AU2015243297B2 (en) Poxviral oncolytic vectors
ES2320157T3 (es) Kit de partes diseñado para poner en practica un tratamiento atitumoral o antivirico en un mamifero.
JP2008545653A (ja) 抗腫瘍組成物及び方法
Nawa et al. Gene directed enzyme prodrug therapy for ovarian cancer: could GDEPT become a promising treatment against ovarian cancer?
US9687515B2 (en) Poxviral oncolytic vectors
HK1160798B (en) Purine nucleoside phosphorylase as enzymatic activator of nucleoside prodrugs
Aghi Improving the efficacy of chemosensitizing brain tumor gene therapies
Factor Pulmonary and Critical Care Medicine, COLUMBIA/Michael Reese Hospital
HK1230971B (en) Poxviral oncolytic vectors
HK1230971A1 (en) Poxviral oncolytic vectors
TW200533752A (en) Pan cancer oncolytic vectors and methods of use thereof
HK1141541B (en) Poxviral oncolytic vectors
HK1082958A1 (zh) 在肿瘤细胞中选择性增殖的肿瘤溶解病毒

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090518

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090518

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20101203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101214